Meropenem: Difference between revisions

Jump to navigation Jump to search
m (Protected "Meropenem": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 20: Line 20:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


'''Meropenem''' is an ultra-broad spectrum injectable [[antibiotic]] used to treat a wide variety of infections, including [[meningitis]] and [[pneumonia]]. It is a [[beta-lactam]] and belongs to the subgroup of [[carbapenem]], similar to [[imipenem]] and [[ertapenem]]. Meropenem was originally developed by [[Sumitomo Pharmaceuticals]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Merrem&reg;''' and '''Meronem&reg;'''. Other brand names include '''Mepem&reg;''' (Taiwan) and '''Meropen&reg;''' (Japan, Korea). It gained [[FDA]] approval in July 1996. It penetrates well into many tissues and body fluids including the [[cerebrospinal fluid]], [[bile]], [[heart valve]]s, [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref>  
'''Meropenem''' is an ultra-broad spectrum injectable [[antibiotic]] used to treat a wide variety of infections, including [[meningitis]] and [[pneumonia]]. It is a [[beta-lactam]] and belongs to the subgroup of [[carbapenem]], similar to [[imipenem]] and [[ertapenem]]. Meropenem was originally developed by [[Sumitomo Pharmaceuticals]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Merrem&reg;''' and '''Meronem&reg;'''. Other brand names include '''Mepem&reg;''' (Taiwan) and '''Meropen&reg;''' (Japan, Korea). It gained [[FDA]] approval in July 1996. It penetrates well into many tissues and body fluids including the [[cerebrospinal fluid]], [[bile]], [[heart valve]]s, [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref>  
Line 42: Line 42:
{{CephalosporinAntiBiotics}}
{{CephalosporinAntiBiotics}}
[[Category:Carbapenem antibiotics]]
[[Category:Carbapenem antibiotics]]
{{SIB}}
 
[[zh:美羅培南]]
[[zh:美羅培南]]
{{WH}}
{{WH}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 17:20, 9 August 2012

Meropenem
File:Meropenem.svg
Clinical data
Pregnancy
category
  • B
Routes of
administration
IV
ATC code
Legal status
Legal status
  • ℞-only (U.S.)
Pharmacokinetic data
Bioavailability100%
Protein bindingApproximately 2%.
Elimination half-life1 hour
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H25N3O5S
Molar mass383.464 g/mol

WikiDoc Resources for Meropenem

Articles

Most recent articles on Meropenem

Most cited articles on Meropenem

Review articles on Meropenem

Articles on Meropenem in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Meropenem

Images of Meropenem

Photos of Meropenem

Podcasts & MP3s on Meropenem

Videos on Meropenem

Evidence Based Medicine

Cochrane Collaboration on Meropenem

Bandolier on Meropenem

TRIP on Meropenem

Clinical Trials

Ongoing Trials on Meropenem at Clinical Trials.gov

Trial results on Meropenem

Clinical Trials on Meropenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Meropenem

NICE Guidance on Meropenem

NHS PRODIGY Guidance

FDA on Meropenem

CDC on Meropenem

Books

Books on Meropenem

News

Meropenem in the news

Be alerted to news on Meropenem

News trends on Meropenem

Commentary

Blogs on Meropenem

Definitions

Definitions of Meropenem

Patient Resources / Community

Patient resources on Meropenem

Discussion groups on Meropenem

Patient Handouts on Meropenem

Directions to Hospitals Treating Meropenem

Risk calculators and risk factors for Meropenem

Healthcare Provider Resources

Symptoms of Meropenem

Causes & Risk Factors for Meropenem

Diagnostic studies for Meropenem

Treatment of Meropenem

Continuing Medical Education (CME)

CME Programs on Meropenem

International

Meropenem en Espanol

Meropenem en Francais

Business

Meropenem in the Marketplace

Patents on Meropenem

Experimental / Informatics

List of terms related to Meropenem


Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]

Mechanism of action

Meropenem is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamases or cephalosporinases. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[2] Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.

Indications

The spectrum of action includes many gram-positive and gram-negative bacteria and even some anaerobic bacteria. The overall spectrum is similar to imipenem although meropenem is more active against Enterobacteriaceae and less active against gram-positive bacteria. It is also very resistant to extended-spectrum beta lactamases but may be more susceptible to metallo-beta-lactamases.[1] However, meropenem should not be used to treat MRSA infections.

Administration

Meropenem must be administered intravenously. It is supplied as a white crystalline powder to be dissolved in 5% monobasic potassium phosphate solution.

Common adverse effects

The most common adverse effects are diarrhea (4.8%), nausea and vomiting (3.6%), injection-site inflammation (2.4%), headache (2.3%), rash (1.9%), and thrombophlebitis (0.9%).[2] Many of these adverse effects were observed in the setting of severely ill individuals who were already taking many medications. Meropenem also has a reduced potential for causing seizures in comparison with imipenem.

References

  1. 1.0 1.1 AHFS DRUG INFORMATION® 2006 (2006 ed ed.). American Society of Health-System Pharmacists. 2006.
  2. 2.0 2.1 Mosby's Drug Consult 2006 (16 ed ed.). Mosby, Inc. 2006.


Template:WH Template:WikiDoc Sources